Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study

Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
Annalisa PaviglianitiAnnalisa Ruggeri

Abstract

Allogeneic stem cell transplantation is an alternative for patients with relapsed or refractory Hodgkin lymphoma (HL), but only limited data on unrelated umbilical cord blood transplantation (UCBT) are available. We analyzed 131 adults with HL who underwent UCBT in European Society for Blood and Marrow Transplantation centers from 2003 to 2015. Disease status at UCBT was complete remission (CR) in 59 patients (47%), and almost all patients had received a previous autologous stem cell transplantation. The 4-year progression-free survival (PFS) and overall survival (OS) were 26% (95% confidence interval [CI], 19% to 34%) and 46% (95% CI, 37% to 55%), respectively. Relapse incidence was 44% (95% CI, 36% to 54%), and nonrelapse mortality (NRM) was 31% (95% CI, 23% to 40%) at 4 years. In multivariate analysis refractory/relapsed disease status at UCBT was associated with increased relapse incidence (hazard ratio [HR], 3.14 [95% CI, 1.41 to 7.00], P = .005) and NRM (HR, 3.61 [95% CI, 1.58 to 8.27], P = .002) and lower PFS (HR, 3.45 [95% CI, 1.95 to 6.10], P < .001) and OS (HR, 3.10 [95% CI, 1.60 to 5.99], P = .001). Conditioning regimen with cyclophosphamide + fludarabine + 2 Gy total body irradiation (Cy+Flu+2GyTBI) was associated w...Continue Reading

References

Mar 7, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SuredaUNKNOWN Grupo Español de Linformas/Transplante Autólogo de Médula Osea Spanish Cooperative Group
Oct 23, 2008·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Lauri M BurroughsDavid G Maloney
Jan 27, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Claudio G BrunsteinJohn E Wagner
Nov 5, 2010·The New England Journal of Medicine·Anas YounesAndres Forero-Torres
Dec 16, 2010·British Journal of Haematology·Paolo CorradiniLucia Farina
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Anas YounesRobert Chen
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Sep 30, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H BeközB Ferhanoglu
Nov 13, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jingmei HsuKoen van Besien
Mar 10, 2018·Expert Review of Hematology·Avyakta Kallam, James O Armitage

❮ Previous
Next ❯

Citations

Feb 8, 2020·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giancarlo FatobeneMary Eapen
May 23, 2020·Bone Marrow Transplantation·Nobuhiko ImahashiUNKNOWN Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation
Feb 16, 2019·Stem Cells International·Quan ZhuangYingzi Ming

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

© 2022 Meta ULC. All rights reserved